Vimizim and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Vimizim (elosulfase alfa), especially for people who are male, 20-29 old, have been taking the drug for 5 - 10 years also take Zantac, and have Bronchospasm.

The study is created by eHealthMe based on reports of 4,772 people who have side effects when taking Vimizim from the FDA, and is updated regularly.

What is Vimizim?

Vimizim has active ingredients of elosulfase alfa. eHealthMe is studying from 4,772 Vimizim users. Check the latest studies of Vimizim.

On Jul, 27, 2026

4,772 people reported to have side effects when taking Vimizim.
Among them, 34 people (0.71%) died.

Among these 34 people:

How long have people been on Vimizim when they died? *

What is the gender of people who died when taking Vimizim? *

female: 35 %
male: 65 %

What is the age of people who died when taking Vimizim? *

What are other drugs people take besides Vimizim? *

What are other side effects people have before they died? *

Malaise (a feeling of general discomfort or uneasiness): 3 people, 8.82%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 2 people, 5.88%
Dyspnea (difficult or laboured breathing): 2 people, 5.88%
Pneumonia: 2 people, 5.88%
Walking Disability: 2 people, 5.88%
Salivary Hypersecretion (excess saliva secretion): 1 person, 2.94%
Respiratory Disorder (respiratory disease): 1 person, 2.94%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 2.94%
Breathing - Slowed Or Stopped: 1 person, 2.94%
Cardiac Disorder: 1 person, 2.94%

What are the existing conditions these people have? *

Oesophagitis (inflammation of oesophagus): 2 people, 5.88%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 2 people, 5.88%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.88%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 2 people, 5.88%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 2.94%
Aortic Valve Incompetence: 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimizim:

Vimizim (4,772 reports)

Expand to all the drugs that have ingredients of elosulfase alfa:

Death and drugs with ingredients of elosulfase alfa (44 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vimizim:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,116 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elosulfase alfa (the active ingredients of Vimizim) and Vimizim (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.